HK1211293A1 - Brutons tyrosine kinase inhibitors - Google Patents

Brutons tyrosine kinase inhibitors

Info

Publication number
HK1211293A1
HK1211293A1 HK15112141.6A HK15112141A HK1211293A1 HK 1211293 A1 HK1211293 A1 HK 1211293A1 HK 15112141 A HK15112141 A HK 15112141A HK 1211293 A1 HK1211293 A1 HK 1211293A1
Authority
HK
Hong Kong
Prior art keywords
tyrosine kinase
kinase inhibitors
brutons tyrosine
brutons
inhibitors
Prior art date
Application number
HK15112141.6A
Other languages
English (en)
Chinese (zh)
Inventor
‧施普林格
‧戴瓦達斯
‧加蘭
‧格拉佩豪斯
‧韓
‧霍克曼
‧休斯
‧薩亞
‧施努特
‧賽爾內斯
‧沃克
‧萬
‧邢
‧查普夫
‧施密特
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1211293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of HK1211293A1 publication Critical patent/HK1211293A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15112141.6A 2012-11-02 2015-12-09 Brutons tyrosine kinase inhibitors HK1211293A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
US201361772028P 2013-03-04 2013-03-04
PCT/IB2013/059846 WO2014068527A1 (en) 2012-11-02 2013-11-01 Bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1211293A1 true HK1211293A1 (en) 2016-05-20

Family

ID=49596360

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112141.6A HK1211293A1 (en) 2012-11-02 2015-12-09 Brutons tyrosine kinase inhibitors

Country Status (27)

Country Link
US (4) US20150291554A1 (ko)
EP (1) EP2914586B1 (ko)
JP (1) JP6178861B2 (ko)
KR (1) KR101668574B1 (ko)
CN (1) CN105008344B (ko)
AP (1) AP2015008381A0 (ko)
AU (1) AU2013340345B2 (ko)
BR (1) BR112015009624A2 (ko)
CA (1) CA2888960C (ko)
CL (1) CL2015001168A1 (ko)
CO (1) CO7350624A2 (ko)
CR (1) CR20150228A (ko)
DO (1) DOP2015000100A (ko)
EA (1) EA201500393A1 (ko)
ES (1) ES2625944T3 (ko)
GE (1) GEP201606597B (ko)
HK (1) HK1211293A1 (ko)
IL (1) IL238571A0 (ko)
MD (1) MD20150035A2 (ko)
MX (1) MX2015005422A (ko)
NI (1) NI201500059A (ko)
PE (1) PE20151070A1 (ko)
PH (1) PH12015500940A1 (ko)
SG (1) SG11201502893WA (ko)
TN (1) TN2015000168A1 (ko)
TW (1) TWI518080B (ko)
WO (1) WO2014068527A1 (ko)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104603124B (zh) 2012-08-10 2018-04-17 勃林格殷格翰国际有限公司 用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物
AU2013312296B2 (en) 2012-09-10 2017-06-22 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014151620A1 (en) 2013-03-14 2014-09-25 Boehringer Ingelheim International Gmbh 5-thiazolecarboxamide dervatives and their use as btk inhibitors
KR102311329B1 (ko) * 2013-03-15 2021-10-14 얀센 파마슈티카 엔.브이. 약제를 제조하기 위한 방법 및 중간체
WO2014152114A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
JP6486359B2 (ja) * 2013-08-19 2019-03-20 タリス バイオメディカル エルエルシー 多ユニット薬物送達デバイス及び方法
KR102272792B1 (ko) * 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
JP6486954B2 (ja) * 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのピラゾール化合物
EA033900B1 (ru) 2014-02-21 2019-12-06 Принсипиа Биофарма Инк. СОЛЕВЫЕ И АМОРФНЫЕ ФОРМЫ 2-[(3R)-3-[4-АМИНО-3-(2-ФТОР-4-ФЕНОКСИФЕНИЛ)ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ]ПИПЕРИДИН-1-КАРБОНИЛ]-4-МЕТИЛ-4-[4-(ОКСЕТАН-3-ИЛ)ПИПЕРАЗИН-1-ИЛ]ПЕНТ-2-ЕННИТРИЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ПУЗЫРЧАТКИ ОБЫКНОВЕННОЙ И ПУЗЫРЧАТКИ ЛИСТОВИДНОЙ С ИХ ПРИМЕНЕНИЕМ
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CN106687446B (zh) * 2014-07-18 2020-04-28 百济神州(北京)生物科技有限公司 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
EA036269B1 (ru) 2014-12-18 2020-10-21 Принсипиа Биофарма Инк. Лечение пузырчатки
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA2998796A1 (en) 2015-09-16 2017-03-23 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PL3377484T3 (pl) * 2015-11-17 2024-04-08 Merck Patent Gmbh Metody dla terapii stwardnienia rozsianego z użyciem związków pirymidynowych i pirydynowych z aktywnością inhibitorową dla btk
PE20220502A1 (es) * 2015-12-16 2022-04-07 Loxo Oncology Inc Compuestos utiles como inhibidores de cinasa
EP3390390B1 (en) 2015-12-16 2021-09-01 Boehringer Ingelheim International Gmbh Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
EP3402789B1 (en) 2016-01-13 2020-03-18 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
US10882843B2 (en) 2016-05-16 2021-01-05 Suzhou Sinovent Pharmaceuticals Co., Ltd. 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof
US20190231784A1 (en) 2016-06-29 2019-08-01 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
EP3548046A2 (en) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
WO2019091440A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i
CN111225912B (zh) * 2017-11-10 2020-11-10 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法
WO2019091438A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
CN108530436B (zh) * 2018-05-17 2020-12-29 黄传满 一种吡唑类化合物及其制备方法和应用
WO2020072964A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020280904A1 (en) * 2019-05-21 2021-11-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a BTK inhibitor
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202317099A (zh) * 2020-09-10 2023-05-01 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023284765A1 (zh) * 2021-07-16 2023-01-19 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
TW202342444A (zh) * 2022-02-04 2023-11-01 美商理通製藥公司 特定化學實體、組合物及方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
JP2006515828A (ja) * 2001-09-27 2006-06-08 スミスクライン・ビーチャム・コーポレイション 化学化合物
CA2648923A1 (en) * 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
CN102887900B (zh) 2006-09-22 2015-04-29 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
WO2009011880A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
EP3311818A3 (en) * 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
DK2473049T3 (en) 2009-09-04 2019-04-01 Biogen Ma Inc INHIBITORS OF BRUTON'S TYROSINKINASE
US8685969B2 (en) * 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
CN104603124B (zh) * 2012-08-10 2018-04-17 勃林格殷格翰国际有限公司 用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10105632B2 (en) 2014-04-09 2018-10-23 Donaldson Company, Inc. Self-supporting folded sheet material, filter elements, and methods
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
PE20151070A1 (es) 2015-08-01
EP2914586B1 (en) 2017-04-05
AU2013340345A1 (en) 2015-04-30
MD20150035A2 (ro) 2015-10-31
DOP2015000100A (es) 2015-12-31
CA2888960A1 (en) 2014-05-08
US20190202798A1 (en) 2019-07-04
KR20150075114A (ko) 2015-07-02
US10815213B2 (en) 2020-10-27
KR101668574B1 (ko) 2016-10-24
EP2914586A1 (en) 2015-09-09
TW201431851A (zh) 2014-08-16
MX2015005422A (es) 2015-08-05
AP2015008381A0 (en) 2015-04-30
TWI518080B (zh) 2016-01-21
CL2015001168A1 (es) 2015-07-10
CN105008344B (zh) 2017-07-25
GEP201606597B (en) 2017-01-10
TN2015000168A1 (fr) 2016-10-03
JP6178861B2 (ja) 2017-08-09
CR20150228A (es) 2015-09-14
NI201500059A (es) 2015-06-05
US20170283393A1 (en) 2017-10-05
US20210002251A1 (en) 2021-01-07
CA2888960C (en) 2017-08-15
AU2013340345B2 (en) 2016-10-27
CN105008344A (zh) 2015-10-28
JP2015535277A (ja) 2015-12-10
IL238571A0 (en) 2015-06-30
WO2014068527A1 (en) 2014-05-08
US20150291554A1 (en) 2015-10-15
EA201500393A1 (ru) 2016-05-31
CO7350624A2 (es) 2015-08-10
SG11201502893WA (en) 2015-05-28
ES2625944T3 (es) 2017-07-21
PH12015500940A1 (en) 2015-06-29
BR112015009624A2 (pt) 2017-11-14
US10266513B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
HK1211293A1 (en) Brutons tyrosine kinase inhibitors
IL277951A (en) Pyrimidinyls are tyrosine kinase inhibitors
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
HK1208442A1 (en) Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk
HK1210161A1 (en) Heteroaromatic compounds as brutons tyrosine kinase (btk) inhibitors (btk)
HK1194381A1 (en) Inhibitors of brutons tyrosine kinase
HK1197060A1 (en) Inhibitors of brutons tyrosine kinase
PL2710005T3 (pl) Inhibitory kinazy tyrozynowej
HK1210461A1 (en) Inhibitors of brutons tyrosine kinase
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
HK1206624A1 (en) Brutons tyrosine kinase inhibitors for hematopoietic mobilization
EP2917210A4 (en) KINASE INHIBITORS
HK1210779A1 (en) Inhibitors of brutons tyrosine kinase
HK1209277A1 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6-
HK1200816A1 (en) Inhibitors of brutons tyrosine kinase
EP2934525A4 (en) THIAZOLSUBSTITUTED AMINOPYRIDINE AS MILTSTYROSINKINASE INHIBITOR
EP2988744A4 (en) THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1217695A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
EP2903970A4 (en) SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
HK1215855A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1218416A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1218394A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1209316A1 (en) Substituted picolinamide kinase inhibitors